Leading the way to a cure

Scientific Advisory Board 2009

Mary K. (Peggy) Crow, M.D. (Chair)

Mary K. Crow, M.D. - Scientific Advisory Board Chair

Mary K. Crow, MD, is the Benjamin M. Rosen Professor and Senior Scientist at Hospital for Special Surgery in New York and Professor of Medicine and Immunology at Weill Medical College of Cornell University. At Hospital for Special Surgery, Dr. Crow is Director of Rheumatology Research and Associate Chief of Rheumatology. In addition, she serves as Director of the Autoimmunity and Inflammation Research Program and as Co-Director of the Mary Kirkland Center for Lupus Research.

Dr. Crow earned an MD from Cornell University Medical College and completed an internship and internal medicine residency at New York Hospital in Manhattan. Her rheumatology clinical fellowship training was performed at Hospital for Special Surgery. She also served as a post-doctoral research fellow at Rockefeller University, where she was mentored by Dr. Henry Kunkel, a renowned immunologist who made significant contributions to the understanding of the mechanisms responsible for autoimmune diseases, including rheumatoid arthritis and systemic lupus erythematosus.

Dr. Crow served as President of the American College of Rheumatology (2005-2006) and is very active in the rheumatology research community. Her own research has focused on the induction and regulation of human autoimmunity. She was among the first to characterize the functional properties of human dendritic cells and has studied self-reactive T cells in the prototype systemic autoimmune diseases, systemic lupus erythematous and rheumatoid arthritis. She continues to investigate the underlying triggers of autoimmune disease and the cellular and cytokine mediators of uncontrolled immune system activation in those disorders. She has published more than seventy scientific papers and has received research grant support from the NIH, the Arthritis Foundation, the Alliance for Lupus Research, the Lupus Research Institute, and the Mary Kirkland Center for Lupus Research. She was named an “Arthritis Hero” by the Arthritis Foundation in 2001.

John Atkinson, MD

John Atkinson, MD

John Atkinson received his B.A. and M.D. degrees from the University of Kansas. His training in internal medicine was at the Massachusetts General Hospital and the National Institutes of Health. His postdoctoral research training was with Sheldon Wolff and Michael Frank at the National Institutes of Health and with Charles Parker and Donald Shreffler at Washington University. He has been on the faculty of Washington University since 1976 and directed the Division of Rheumatology from 1976 to 1992. He was an investigator of the Howard Hughes Medical Institute from 1976 to 1992. He was Physician-in-Chief at Barnes Hospital and Adolphus Busch Professor and Head of John Milliken Department of Medicine from 1992 to 1996. Dr. Atkinson is currently Professor of Medicine and of Molecular Microbiology. He is the first Samuel B. Grant Professor.

Jeffery A. Bluestone, PhD, UCSF

Jeffery A. Bluestone, PhD, UCSF

Dr. Bluestone, studies why the human body's immune system rejects or tolerates self and transplanted tissue and elucidating the biological basis for immunologic tolerance. He is interested in defining the critical importance of T-cell co-stimulation in T-cell activation, and he has developed a “human” form of the anti-CD3 monoclonal antibody, that in recent clinical trials demonstrated clear efficacy in blocking islet transplant reject and the progression of autoimmunity. In addition he is the Director of The Immune Tolerance Network, an NIH funded program to advance clinical research on immune tolerance. The ITN brings together more than 70 of the world's leading scientific researchers and clinical specialists from nearly 40 institutions in nine countries to coordinate human clinical testing of new therapies designed to bring about immune tolerance in kidney or insulin-producing beta cell transplantation, autoimmune diseases such as type I diabetes, arthritis or lupus and immunologic treatments of asthma and allergic diseases. Finally, he has embarked on an effort to try and bring cellular therapy to the clinic in lupus and diabetes. Over the last few years, the critical importance of regulatory T lymphocytes in the maintenance of self-tolerance has been established.

Andrew Chan, MD, PhD

Andrew Chan, MD, PhD

Dr. Andrew Chan is currently Vice President, Research-Immunology for Genentech, Inc. His research interests have focused on how T and B cells regulate immune cell development and function. He has served on the faculty and Attending Rheumatologist at Washington University School of Medicine (St. Louis, MO), and an Associate Investigator of the Howard Hughes Medical Institute.

Barbara K. Finck, MD

Barbara K. Finck, MD

Dr. Finck is the Senior Vice President, Chief Medical Officer of Osprey Pharmaceuticals LTD. Prior to this position she served as Vice President, Clinical Development of PDL BioPharma, Inc., where she was responsible for the medical and clinical operations for eight therapeutic candidates in the areas of autoimmune diseases, oncology and cardiology. Previously, she held the position of Vice President, Clinical Development at Eos Biotechnology, Inc. from 2001 until PDL BioPharma purchased the company in April 2003.

As Medical Director at Immunex Corp. for five years, Dr. Finck was responsible for clinical development of Enbrel(R) for rheumatoid arthritis in adults and children. Dr. Finck also served as the Clinical Program Manager and Medical Monitor at ALZA Corp and as Assistant Professor of Medicine at the University of California, San Francisco (UCSF). Dr. Finck earned her bachelor's degree in Physiological Psychology from the University of California, Santa Barbara, an M.D. from UCSF, and is board certified in internal medicine and rheumatology.

David Hafler, MD

David Hafler, MD

Dr. Hafler is the Jack, Sadie and David Breakstone Professor of Neurology (Neuroscience) at the Harvard Medical School and a Physician at the Brigham and Women’s Hospital and the Massachusetts General Hospital in Boston. He graduated Emory University with combined B.S. and M.Sc. degrees in biochemistry, and the University of Miami School of Medicine. He then completed his internship in internal medicine at Johns Hopkins followed by a neurology residency at Cornell Medical Center-New York Hospital in New York. Dr. Hafler received training in immunology at the Rockefeller University then at Harvard where he joined the faculty in 1984. He is a member of the Program in Immunology at Harvard Medical School and is on the faculty of the Harvard-MIT Health Science and Technology program where he has been actively involved in the training of graduate students and post-doctoral fellows. Dr. Hafler has been elected to membership in the American Society of Clinical Investigation, The American Neurological Association, the Alpha Omega Society, and was a Harvey Weaver Scholar of the National Multiple Sclerosis Society. He is currently a member of the editorial boards for Journal of Clinical Investigation, Cellular Immunology, Clinical Immunology, and Journal of Neuroimmunology, and is co-founder of the Federation of Clinical Immunology Societies. Dr. Hafler heads the Laboratory of Molecular Immunology in the Center for Neurologic Diseases, Harvard Medical School. He is a clinical scientist with a research interest in understanding the mechanism of autoimmunity with a particular interest in inflammatory central nervous system diseases. He leads the NIH Autoimmunity Prevention Center Grant at Harvard, and recently received the 1st National Multiple Sclerosis five year Collaborative Center Award with Dr. Eric Lander of the Whitehead Institute for tackling the MS genetic effort.

Brian Kotzin, MD

Brian Kotzin, MD

Dr. Brian Kotzin is Vice President, Global Clinical Development at Amgen in California. Prior to joining Amgen, Dr. Kotzin was a professor in the departments of medicine and immunology, and a co-head of the Division of Clinical Immunology at the University of Colorado Health Sciences Center in Denver. Dr. Kotzin served as chairman of the National Institute of Allergy and Infectious Diseases (NIH) Autoimmunity Centers of Excellence Steering Committee, and was a director and principal investigator at the Denver Autoimmunity Center of Excellence. Dr. Kotzin earned his medical degree from Stanford University School of Medicine and completed his residency at Beth Israel Hospital in Boston. He completed a fellowship in Rheumatology (Medicine) at Beth Israel Hospital and a fellowship in immunology at Stanford University.

Peter E. Lipsky , MD

Dr Peter E. Lipsky is the National Institute of Health's (NIH) Chief of Autoimmunity for the Intramural Research Program at the National Institute of Arthritis and Muscoskeletal and Skin Diseases (NIAMS). He received his medical degree from the New York University School of Medicine and spent much of his career at the University of Texas Medical Center, initially as Instructor in Internal Medicine and later as Professor of Internal Medicine and Microbiology. Later appointments at the University of Texas Medical Center (1984-1999) included Director of the Harold C Simmons Arthritis Research Center, Co-Director of the Immunology Graduate Program at the Southwestern Graduate School of Biomedical Sciences, and Director of the Rheumatic Disease Division of the Department of Internal Medicine. Dr Lipsky was named the Harold C Simmons Professor in Arthritis Research in 1995, a position he held for 5 years.

Dr Lipsky's major research interests are B-cell biology, both in normal and autoimmune disease settings, and the generation of the immunoglobulin repertoire, and has authored over 500 articles. He serves on numerous journal editorial boards, and is the Co-Editor of Arthritis Research and Therapy and the Editor in Chief for Nature Clinical Practice Rheumatology. He has been awarded numerous prizes, including the Carol Nachman Prize in 2001, the Lee C. Howley Prize for Arthritis Research in 2002, the American College of Rheumatology's Distinguished Investigator Award in 2002, and the Japan Rheumatology Prize 2006.

Randolph J. Noelle, PhD

Dr. Noelle is a Professor of Microbiology at Dartmouth Medical School. He received his Ph.D. from Albany Medical College in 1980; was a post-doctoral fellow at the University of Texas Health Science Center at Dallas from 1980-1984; and in 1984, he joined the faculty of Dartmouth Medical School as an Assistant Professor.

Dr. Noelle's laboratory has identified a novel membrane protein expressed on helper T lymphocytes (Th), CD154. The receptor for CD154 is CD40 is expressed on B lymphocytes and antigen-presenting cells. Dr. Noelle's laboratory is also actively involved in trying to unravel the biochemical signaling cascade that transpire as a consequence of CD40 signaling.

Return to ALR SAB home

ALR SAB 2008


1.5 million

people in the U.S. have Lupus.

90 million

dollars committed to lupus research by the Alliance for Lupus Research.

We're walking across the United States to raise awareness and funds for lupus research.

Can't make it? Join our National Virtual Walk to participate anytime, anywhere.

Show your support by visiting the Alliance for Lupus Research online store. Discover the perfect gift, or prepare for a walk with our selection of apparel and accessories.

Powered by Convio
nonprofit software